Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients

Journal of Cystic Fibrosis

Volumn 7, Issue 1, 2008, Pages 79-84

  Wilms, E B ^a   Touw, D J ^a   Heijerman, H G M ^b  

^a Central Hospital Pharmacy   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

Author keywords

Azithromycin; Once weekly dosing; Penetration; Pharmacokinetics; Polymorphonuclear neutrophil; Sputum

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG PENETRATION; DRUG SPUTUM LEVEL; DRUG TOLERABILITY; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; HUMAN CELL; MALE; NAUSEA; NEUTROPHIL; PSEUDOMONAS AERUGINOSA;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUTROPHILS; SPUTUM;

EID: 38049053588     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2007.05.005     Document Type: Article

References (20)

1. Equi A., Balfour-Lynn I.M., Bush A., and Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360 (2002) 978-984
2. Jaffe A., Francis J., Rosenthal M., and Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 351 (1998) 420
3. Patel K.B., Xuan D., Tessier P.R., Russomanno J.H., Quintiliani R., and Nightingale C.H. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 40 (1996) 2375-2379
4. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., et al., Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290 (2003) 1749-1756
5. Wolter J., Seeney S., Bell S., Bowler S., Masel P., and McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57 (2002) 212-216
6. Clement A., Tamalet A., Leroux E., Ravilly S., Fauroux B., and Jais J.P. Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 61 (2006) 895-902
7. Wilms E., Touw D., and Heijerman H. Pharmacokinetics of azithromycin in plasma, whole blood, polymorphonuclear neutrophils and sputum during chronic use in patients with cystic fibrosis. Ther Drug Monit 28 (2006) 219-225
8. Tateda K., Comte R., Pechere J.C., Kohler T., Yamaguchi K., and Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 45 (2001) 1930-1933
9. Tateda K., Ishii Y., Matsumoto T., Furuya N., Nagashima M., Matsunaga T., et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother 40 (1996) 2271-2275
10. Takeoka K., Ichimiya T., Yamasaki T., and Nasu M. The in vitro effect of macrolides on the interaction of human polymorphonuclear leukocytes with Pseudomonas aeruginosa in biofilm. Chemotherapy 44 (1998) 190-197
11. Amsden G.W. Anti-inflammatory effects of macrolides-an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?. J Antimicrob Chemother 55 1 (2005) 10-21
12. Havlir D.V., Dube M.P., Sattler F.R., Forthal D.N., Kemper C.A., Dunne M.W., et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 335 (1996) 392-398
13. Pfizer Ltd. Sandwich UK. Summaries of Product Characteristics Zithromax.www.emc.medicines.org.uk. Date last updated: 17 July 2006. Date last accessed: 20 July 2006.
14. Wilms E., Trumpie H., Veenendaal W., and Touw D. Quantitative determination of azithromycin in plasma, blood and isolated neutrophils by high-performance liquid chromatography using pre-column derivatization with 9-fluorenylmethyloxycarbonyl chloride and fluorescence detection. J Chromatogr B Biomed Sci Appl 814 (2005) 37-42
15. Proost J.H., and Meijer D.K. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 22 (1992) 155-163
16. D'Argenio D.Z. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 9 (1981) 739-756
17. Fassbender M., Lode H., Schiller C., Andro R., Goetschi B., Borner K., et al. Comparative pharmacokinetics of macrolide antibiotics and concentrations achieved in polymorphonuclear leukocytes and saliva. Clin Microbiol Infect 1 4 (1996) 235-243
18. Hand W.L., and Hand D.L. Characteristics and mechanism of azithromycin accumulation in human polymorphonuclear leukocytes. Int J Antimicrob Agents 18 (2001) 419-425
19. Amsden G.W., and Gray C.L. Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. Antimicrob Chemother 47 (2001) 61-66
20. Sugie M., Asakura E., Zhao Y.L., Torita S., Nadai M., Baba K., et al. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother 48 (2004) 809-814